Sunday, June 7, 2009

Drawdown curve



Coming along now in various facets in designing the backtesting software. This past week completed adding equity and margin limits to both systems as well as wrote a piece to run market correlation studies. I've included many more performance statistics, including robust statistics mentioned in Curtis Faith's Way of the Turtle, which I recommend for anyone designing systems. And, finally, I can now generate drawdown curves which is a nice complement to the equity curves I have been spitting out. Please enjoy as I do!

Moving ahead, I need to account for contract rollovers in my simulation as well as formally verify the Support and Resistance system output in Excel. I also am ready to buy some data -- finally! I will buy data from two vendors for about 70 markets, domestic and foreign. It runs between $100 for $250 from what I have seen, although I do not know how reliable these vendors' collections are. I'll have to write a data scanner to test the data for inconsistencies before I can employ them.

Also, here is what my system output is looking like at the moment:

Exponential Crossover System Backtest
Side = Both
Slow Lag = 325
Fast Lag = 85
ATR Lag = 20
ATR Multi = 5
WarmUp = 20

Starting Equity = 1000000
Heat = 0.1
Start date = 12/31/1974
End date = 9/27/2005
Ending Equity = 110550027.500
ICAGR = 0.1531
RAR = 0.1328
Max. Drawdown = 0.6037
Longest Drawdown = 91 mos.
Seykota Bliss = 0.2535
R-cubed = 0.1105
-----------------------------------
# of Trades = 29
Avg. Trade Length = 22.5 mos.
Max. Trade Length = 49 mos.
Win Percentage = 0.5517
Max. Losing Streak = 4
Avg. Trade = 3777893
Avg. Profit = 7170253
Avg. Loss = 397319
Avg. Profit / Avg. Loss = 18.05
Expectancy = 3777892.84
T-test = 11.87
Optimal F = 1305581
-----------------------------------
Max % of Account Employed = 1.0005
# Margin Calls = 14
# Forced-liquidations = 2
# Pared-backed Positions = 8
# Insufficent Funds for Entry = 0
Total commissions = 49365.00
************************************

Be well!!

No comments:

Post a Comment